Aptar Pharma pulled the trigger on a deal for Pharmaxis’ Orbital high payload dry powder inhaler technology, paying $2.5 million for a worldwide license with the same again to follow if it chooses to ...

The flurry of business development activity at Aptar continues. Having made moves for injectable drug delivery and digital therapeutic players in recent weeks, Aptar has now nabbed (PDF) an option on ...

Most people with asthma and other lung diseases have no idea that commonly prescribed inhalers are helping make the planet warmer. Each puff has about the same climate impact as driving a gas-powered ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...

The pros and cons to using a dry powder inhaler as treatment for chronic obstructive pulmonary disease. Neil Minkoff, MD: Dr Drummond, we’ve talked a little bit about the differences. You brought some ...

Switching from a metered dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...

During an asthma check-up at Brigham and Women's Hospital in Boston, Joel Rubinstein gets a surprising pitch — for the planet, as well as his health. His pulmonologist, Dr. Miguel Divo, explains that ...

Switching from a metered-dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...